- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears CT-Based AI Software for Detecting Enlarged Heart Chambers
The AI-enabled AutoChamber software also garnered the FDA’s breakthrough device designation for opportunistic detection of enlarged heart chambers on non-contrast CT scans.
The Food and Drug Administration (FDA) has granted its breakthrough device designation and 510(k) clearance for AutoChamber™, an artificial intelligence (AI)-enabled software for computed tomography (CT) that may facilitate early detection of enlarged heart chambers.
Leveraging deep learning-based AI, the AutoChamber software calculates the volume of cardiac chambers and left ventricular wall mass in 15 to 20 seconds, according to HeartLung Technologies, the manufacturer of AutoChamber.
The newly FDA-cleared AutoChamber software leverages deep learning-based AI to calculate the volume of cardiac chambers and left ventricular wall mass in 15 to 20 seconds, according to HeartLung Technologies, the developer of the software. (Images courtesy of HeartLung Technologies.)
The company said AutoChamber, which can be utilized for heart CT and coronary CT angiography (CCTA) scans as well as chest CT for lung cancer screening, may help identify patients who have higher risks for atrial fibrillation, stroke, and heart failure.
“I feel strongly about the opportunity AutoChamber may have to evaluate cardiovascular risk for the millions of persons getting chest CT scans worldwide, in particular for lung cancer screening and other non-cardiac reasons,” noted Nathan Wong, M.D., a professor of director of the Heart Disease Prevention Program within the Division of Cardiology at the University of California, Irvine in Irvine, Calif. “The potential is for identifying those at increased risk who could benefit from earlier intervention to improve outcomes.”
Can Radiomics Bolster Low-Dose CT Prognostic Assessment for High-Risk Lung Adenocarcinoma?
December 16th 2024A CT-based radiomic model offered over 10 percent higher specificity and positive predictive value for high-risk lung adenocarcinoma in comparison to a radiographic model, according to external validation testing in a recent study.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
Study Shows Merits of CTA-Derived Quantitative Flow Ratio in Predicting MACE
December 11th 2024For patients with suspected or known coronary artery disease (CAD) without percutaneous coronary intervention (PCI), researchers found that those with a normal CTA-derived quantitative flow ratio (CT-QFR) had a 22 percent higher MACE-free survival rate.
